International Journal for Doctor of Medicine and  Medical Students (IJDMMS)

Abstract

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease with significant morbidity in pediatric populations. Childhood-onset SLE (cSLE) represents approximately 15–20% of all SLE cases and is often more severe than adult-onset disease, with higher rates of organ involvement, particularly renal and central nervous system complications. The disease is characterized by immune dysregulation, autoantibody production, and immune complex deposition leading to widespread inflammation. Early diagnosis remains challenging due to heterogeneous clinical presentations. This article aims to explore the epidemiology, pathogenesis, clinical features, diagnostic criteria, and current management strategies of pediatric SLE. Special emphasis is placed on advancements in immunotherapy and the importance of multidisciplinary care. Understanding the unique aspects of cSLE is essential for improving outcomes and reducing long-term complications.

Introduction

Systemic lupus erythematosus (SLE) is a prototypical autoimmune disorder characterized by loss of self-tolerance and production of pathogenic autoantibodies. Pediatric SLE, also known as childhood-onset SLE (cSLE), accounts for approximately 15–20% of all lupus cases and typically presents before the age of 18 years (Hiraki et al., 2012). Compared to adult SLE, cSLE is associated with more aggressive disease, higher disease activity, and increased organ involvement (Groot et al., 2020).

The etiology of SLE is multifactorial, involving genetic susceptibility, environmental triggers, hormonal influences, and immune dysregulation. Advances in immunology have revealed critical roles for B cells, T cells, cytokines, and complement pathways in disease development (Tsokos, 2011). In children, early diagnosis is crucial because delayed treatment can lead to irreversible organ damage, particularly lupus nephritis, which remains a major cause of morbidity and mortality.

This article reviews the current understanding of pediatric SLE using the IMRAD format, focusing on its clinical spectrum and modern management strategies.

Methods

A narrative review approach was used to compile current knowledge on childhood SLE. Relevant literature was identified through databases including PubMed, Scopus, and Google Scholar. Keywords included “childhood systemic lupus erythematosus,” “pediatric lupus,” “lupus nephritis in children,” and “autoimmune diseases in pediatrics.”

Inclusion criteria consisted of peer-reviewed articles, systematic reviews, and clinical guidelines published between 2005 and 2024. Studies focusing specifically on pediatric populations were prioritized. Data were extracted regarding epidemiology, pathogenesis, clinical features, diagnostic criteria, and management.

Results

Epidemiology

Childhood SLE is relatively rare, with an incidence of approximately 0.3–0.9 per 100,000 children per year (Hiraki et al., 2012). It predominantly affects females, especially after puberty, with a female-to-male ratio of about 4–5:1. Ethnic variations exist, with higher prevalence and severity observed in Asian, African, and Hispanic populations (Groot et al., 2020).

Pathogenesis

The pathogenesis of cSLE involves a complex interplay of genetic, environmental, and immunological factors.

1. Genetic Factors

Multiple susceptibility genes have been identified, including those related to:

1. HLA class II alleles

2. Complement components (C1q, C2, C4)

3. Interferon regulatory pathways

Deficiencies in early complement proteins are strongly associated with pediatric SLE (Tsokos, 2011).

2. Immune Dysregulation

Key mechanisms include:

1. Loss of immune tolerance

2. Hyperactive B cells producing autoantibodies

3. T-cell dysfunction

4. Increased type I interferon production

Autoantibodies such as anti-dsDNA and anti-Smith antibodies form immune complexes that deposit in tissues, leading to inflammation and damage.

3. Environmental Triggers

Triggers include infections, ultraviolet radiation, and certain medications. These factors can induce apoptosis and release nuclear antigens, promoting autoimmunity.

Clinical Features

cSLE presents with diverse manifestations involving multiple organ systems.

1. Constitutional Symptoms

1. Fever

2. Fatigue

3. Weight loss

2. Mucocutaneous

1. Malar rash

2. Photosensitivity

3. Oral ulcers

4. Alopecia

3. Musculoskeletal

1. Arthralgia

2. Non-erosive arthritis

4. Renal (Lupus Nephritis)

Occurs in up to 60–80% of pediatric cases (Bertsias et al., 2012):

1. Proteinuria

2. Hematuria

3. Hypertension

5. Neurological

1. Seizures

2. Psychosis

3. Cognitive dysfunction

6. Hematological

1. Anemia

2. Leukopenia

3. Thrombocytopenia

Diagnosis

Diagnosis is based on clinical and immunological criteria.

Classification Criteria

1. ACR (American College of Rheumatology)

2. SLICC criteria

3. EULAR/ACR 2019 criteria

Laboratory Findings

1. ANA (high sensitivity)

2. Anti-dsDNA (specific, correlates with disease activity)

3. Anti-Smith antibodies

4. Low complement levels (C3, C4)

5. Elevated ESR

Renal Biopsy

Essential in suspected lupus nephritis for classification and guiding therapy.

Management

General Principles

1. Early diagnosis

2. Organ-specific treatment

3. Prevention of flares

4. Minimization of drug toxicity

Pharmacological Treatment

1. Corticosteroids

1. First-line for acute flares

2. Mechanism: Anti-inflammatory and immunosuppressive

3. Used in moderate to severe disease

2. Antimalarials (Hydroxychloroquine)

1. Drug of choice for all patients unless contraindicated

2. Mechanism: Inhibits antigen presentation and toll-like receptor signaling

3. Benefits: Reduces flares and improves survival

3. Immunosuppressive Agents

1. Cyclophosphamide: Severe lupus nephritis

2. Mycophenolate mofetil: Preferred for maintenance therapy

3. Azathioprine: Steroid-sparing agent

4. Biologic Therapy

1. Belimumab: Anti-BLyS monoclonal antibody

2. Rituximab: Anti-CD20 (used in refractory cases)

Non-Pharmacological Management

1. Sun protection

2. Vaccination

3. Nutritional support

4. Psychological counseling

Complications

1. Lupus nephritis leading to renal failure

2. Infections due to immunosuppression

3. Cardiovascular disease

4. Growth retardation in children

Discussion

Childhood SLE presents unique challenges due to its aggressive nature and long disease duration. Early onset is associated with higher disease activity and increased risk of organ damage compared to adult-onset SLE (Groot et al., 2020).

Lupus nephritis remains the most serious complication and a major determinant of prognosis. Early biopsy and aggressive treatment are crucial to prevent chronic kidney disease. Advances in biologic therapies, such as belimumab, have shown promise in improving disease control and reducing reliance on corticosteroids (Furie et al., 2011).

Despite therapeutic advances, long-term outcomes are still affected by treatment-related toxicity and disease flares. Therefore, a multidisciplinary approach involving pediatricians, rheumatologists, nephrologists, and psychologists is essential.

Future research should focus on personalized medicine, biomarkers for early diagnosis, and targeted therapies to reduce disease burden.

Conclusion

Childhood-onset systemic lupus erythematosus is a complex autoimmune disease with significant morbidity. It is characterized by multisystem involvement, aggressive course, and need for long-term management. Early diagnosis, appropriate immunosuppressive therapy, and multidisciplinary care are critical in improving outcomes. Advances in immunotherapy offer new hope, but challenges remain in reducing disease burden and improving quality of life in affected children.

References

1. Bertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H., ... & Boumpas, D. T. (2012). Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association guidelines for lupus nephritis. Annals of the Rheumatic Diseases, 71(11), 1771–1782.

2. Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., ... & Stohl, W. (2011). A phase III randomized, placebo-controlled study of belimumab in patients with systemic lupus erythematosus. Arthritis & Rheumatism, 63(12), 3918–3930.

3. Groot, N., Shaikhani, D., Teng, Y. K. O., de Leeuw, K., Bijl, M., Dolhain, R. J., & Beresford, M. W. (2020). Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis & Rheumatology, 72(2), 290–299.

4. Hiraki, L. T., Benseler, S. M., Tyrrell, P. N., Hebert, D., Harvey, E., Silverman, E. D. (2012). Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus. The Journal of Pediatrics, 161(5), 897–902.

5. Tsokos, G. C. (2011). Systemic lupus erythematosus. New England Journal of Medicine, 365(22), 2110–2121.

6. Petri, M., Orbai, A. M., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., ... & Magder, L. S. (2012). Derivation and validation of the SLICC classification criteria for lupus. Arthritis & Rheumatism, 64(8), 2677–2686.

7. Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., ... & Dörner, T. (2019). 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78(9), 1151–1159.

8. Rahman, A., & Isenberg, D. A. (2008). Systemic lupus erythematosus. New England Journal of Medicine, 358(9), 929–939.

9. Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014). Systemic lupus erythematosus. The Lancet, 384(9957), 1878–1888.

10.  Yu, H. H., Chen, P. C., Wang, L. C., Lee, J. H., Lin, Y. T., & Yang, Y. H. (2014). Juvenile-onset systemic lupus erythematosus: A review of clinical features and outcomes. Autoimmunity Reviews, 13(4–5), 463–470.

11.  Brunner, H. I., Gladman, D. D., Ibañez, D., Urowitz, M. D., & Silverman, E. D. (2008). Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis & Rheumatism, 58(2), 556–562.

12.  Smith, E., Al-Abadi, E., Armon, K., Bailey, K., Ciurtin, C., Davidson, J., ... & Beresford, M. W. (2020). Clinical practice guideline for the management of childhood lupus. Rheumatology, 59(7), e1–e23.